Skip to main content
. 2021 Dec 17;22(24):13540. doi: 10.3390/ijms222413540

Figure 4.

Figure 4

MV-based metabolomics allows the differentiation between molecular breast cancer subtypes. The metabolomic profiles of plasma MV from luminal A and luminal B breast cancer patients were compared by targeted mass spectrometry. t-statistics (a) reveal 24 significantly differentially expressed metabolites (unpaired Student’s t-test, relevant metabolites colored in pink). Multiple logistic regression (b) for combined ROC analysis of all 24 metabolites.